Neovascular Macular Degeneration/Wet or Dry Macular Degeneration – AMD is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small spot near the center of the retina and the part of the eye needed for sharp, central vision, which lets us see objects that are straight ahead. In some people, AMD advances so slowly that vision loss does not occur for a long time. In others, the disease progresses faster and may lead to a loss of vision in one or both eyes.
Santen DE-122 36-002 AVANTE– A Multi-Center, Randomized, Double-Masked and Active Controlled Phase II Study Assessing the Efficacy, Safety of Intravitreal Injections of DE-122 in combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Wet Age-related Macular Degeneration- See Study @ ClincalTrials.gov
Genentech Roche GR40549 Portal – A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Chengdu Kanghong Biotechnology Panda KHB-1801 – A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration – See Study @ Clinicaltrials.gov
Genentech Roche GR40548 Archway – A Phase III, Multicenter, Randomized, Open-Label (visual assessor masked), Active Comparator Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Through the Port Delivery System (PDS) in Patients with nAMD.
Novartis CRTH258AUS02 Merlin – A Multi-center, Randomized, Double-Masked Phase IIIA Study to Assess Safety and Efficacy of Brolucizumab 6mg Dosed Q 4 Weeks compared to Q 8 weeks in High Anti-VEGF-Need Patients with Neovascular Age-Related Macular Degeneration (nAMD) – See Study @ Clinicaltrials.gov
VisionCare IMT-PAS-01 – A prospective, multicenter post-approval study of VisionCare’s Implantable Miniature Telescope in patients with bilateral severe to profound central vision impairment associated with end-stage age-related macular degeneration.
IMT-TES 2016 – A Prospective, Multicenter Clinical Trial of the Implantable Miniature Telescope in Pseudophakic Eyes with Central Vision Impairment associated with End-Stage Macular Degeneration
Gemini GEM-NH-001 – A Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA)Who are Carriers of High-Risk Genetic Complement Variants Associated with Dry Age-related Macular Degeneration (AMD).
Gemini GEM-NH-002 – A Prospective Natural History Study to Evaluate Clinical Characteristics and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who Are Carriers of High-Risk Genetic Variants of Complement Factor H (CFH).
Retinal Vein Occlusion – Retinal vein occlusion (RVO) is a common vascular disorder of the retina and one of the most common causes of vision loss worldwide. Specifically, it is the second most common cause of blindness from retinal vascular disease after diabetic retinopathy. RVO is classified according to where the occlusion is located. Occlusion of the central retinal vein at the level of the optic nerve is referred to as central retinal vein occlusion (CRVO). Obstruction at any more distal branch of the retinal vein is referred to as branch retinal vein occlusion (BRVO).
Aerie AR-1105-CS201 – A Phase IIA Multi-Center, Open-Label, Safety and Proof-of-Concept Study to Assess Safety, Tolerability, and Efficacy of AR-1105 in Subjects with Macular Edema Due to Retinal Vein Occlusion (RVO) – See Study @ ClinicalTrials.gov
Uveitis – Uveitis is a general term describing a group of inflammatory diseases that produces swelling and destroys eye tissues. The uvea is the middle layer of the eye and includes the iris, choroid, and ciliary body.
Mallinckrodt MNK61074105 – A Phase 4, Multiple Dose, Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar Gel Subcutaneous Injection in Subjects with Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. See Study @ ClinicalTrials.gov
Diabetic Macular Edema/Diabetic Retinopathy – Diabetic Macular Edema (DME) is an accumulation of fluid in the macula—part of the retina that controls our most detailed vision abilities—due to leaking blood vessels. In order to develop DME, you must first have diabetic retinopathy. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment. Left untreated, these blood vessels begin to build up the pressure in the eye and leak fluid, causing DME.
Boehringer-Ingleheim BI-1386-0012 – A Phase IIA Randomized, Double-Masked, Placebo-Controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics Pharmacokinetics of Orally Administered BI1467335 for 12 Weeks with a 12 Week Follow Up Period in Patients with Nonproliferative Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema.
Opthea OPT302-1003 – Phase 1B/2A Study of OPT302 in Combination with Aflibercept for Persistent Central-Involved Diabetic Macular Edema – See Study @ Clinicaltrials.gov
Mylan MYL1701-P-3001 – A Multi-Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects with Diabetic Macular Edema – See Study @ ClinicalTrials.gov
Genentech Roche GR40398 Rhine – A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema.
Novartis CRTH258B2301 Kestrel – A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase III study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema – See Study @ ClinicalTrials.gov
Kodiak KSI CL-101 – A Phase 1B Open-Label, Multi-Center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects with Wet Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion – See Study @ ClinicalTrials.gov
Leber’s Hereditary Optic Neuropathy –Leber Hereditary Optic Neuropathy (LHON) is the most common inherited mitochondrial disorder and typically affects young males. It typically begins as unilateral progressive optic neuropathy, with sequential involvement of the fellow eye months to years later.
Santhera SNT-IV-005 – External Natural History Controlled, open-label intervention study to assess the efficacy and safety of long-term treatment with Raxone in Leber’s Hereditary Optic Neuropathy – See Study @ ClinicalTrials.gov
Retinitis Pigmentosa – Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous group of inherited retinal disorders characterized by diffuse progressive dysfunction of predominantly rod photoreceptors, with subsequent degeneration of cone photoreceptors, and retinal pigment epithelium (RPE). Visual impairment usually manifests as night blindness and progressive visual field loss.
ReNeuron RN03-CP-0001 – First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal progenitor cells (hRPC) in Patients with Retinitis Pigmentosa (RP) – See Study @ ClinicalTrials.gov